Skip to content
Screener

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
Cardinal Health logo
Cardinal HealthCAH
$1.16B+340%
McKesson logo
McKessonMCK
$1.19B+136%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$49.04M-27.9%
Cencora logo
CencoraCOR
-$2.59B-2,763%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$452.4M+182%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquisition of non-controlling interest(400)
Net cash provided by (used in) financing activities20,306(80,853)
Effect of foreign exchange rate on cash(1,187)(777)
Net decrease in cash, cash equivalents, and restricted cash(173,320)(34,748)
Cash, cash equivalents, and restricted cash - beginning of period312,939118,420
Cash, cash equivalents, and restricted cash - end of period$139,619$83,672
Cash and cash equivalents - end of period$127,637$71,544
Restricted cash - end of period8,6439,642

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s net change in cash?
Amneal Pharmaceuticals, Inc. (AMRX) reported net change in cash of -$64.79M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
Amneal Pharmaceuticals, Inc.'s net change in cash decreased by 524.1% year-over-year, from $15.28M to -$64.79M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s net change in cash?
Over 2 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s net change in cash has grown at a -6.3% compound annual growth rate (CAGR), from -$221.51M to $194.52M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Amneal Pharmaceuticals, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude